A research team has identified a potential cause of long-lasting symptoms experienced by COVID-19 patients, often referred to as long-haulers. The findings were published in the journal, The Public Library of Science ONE (PLOS ONE).
Researchers have found that viral vaccines grown in eggs, such as the H1N1 flu vaccine, produce an antibody response against a sugar molecule found in eggs, which could have implications for the effectiveness of these vaccines.
Patients with a type of blood cancer called multiple myeloma had a widely variable response to COVID-19 vaccines—in some cases, no detectable response—pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published in Cancer Cell in June.
In a study published today in the Annals of Internal Medicine, Johns Hopkins Medicine researchers say they believe that, for the first time, there is evidence to show that three doses of vaccine increase antibody levels against SARS-CoV-2 — the virus that causes COVID 19 — more than the standard two-dose regimen for people who have received solid organ transplants.
Abstract: Disease-specific COVID-19 pediatric comorbidity has not been studied effectively todate. Atopy and food anaphylaxis disease states require improved characterization of SARS-CoV-2 infection risk. To provide the first such characterization, we assessed serum samples of a highlyatopic, food anaphylactic, asymptomatic…
In a study published today in the Journal of the American Medical Association (JAMA), Johns Hopkins Medicine researchers show that although two doses of a vaccine against SARS-CoV-2 — the virus that causes COVID 19 — confers some protection for people who have received solid organ transplants, it’s still not enough to enable them to dispense with masks, physical distancing and other safety measures.
Blood draws are no fun.They hurt. Veins can burst, or even roll — like they’re trying to avoid the needle, too.Oftentimes, doctors use blood samples to check for biomarkers of disease: antibodies that signal a viral or bacterial infection, such as SARS-CoV-2, the virus responsible for COVID-19, or cytokines indicative of inflammation seen in conditions such as rheumatoid arthritis and sepsis.
A phase 2 clinical trial providing personalized treatments based on the genetic profile of metastatic tumors in gastroesophageal cancers has found that using customized treatment approaches, and adapting them over time as tumors become resistant, led to higher rates of survival compared to historical controls.
Article title:Immunoglobulin deficiency as an indicator of disease severity in patients with COVID-19 Authors: Faeq Husain-Syed, István Vadász, Jochen Wilhelm, Hans-Dieter Walmrath, Werner Seeger, Horst-Walter Birk, Birgit Jennert, Hartmut Dietrich, Susanne Herold, Janina Trauth, Khodr Tello, Michael Sander, Rory E.…
Irvine, Calif., Dec. 7, 2020 — Using the same strain of yeast that ferments wine and makes dough rise, a team led by University of California, Irvine and Harvard Medical School researchers has developed an in vitro technology that can rapidly hypermutate antibodies. The new technology generates antibodies faster than animal immune systems and better than current synthetic methods, giving researchers the tools for evolving exceptionally potent agents, including therapeutic candidates that target SARS-CoV-2.
Today in Science, researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to prevent and treat COVID-19.
Blocking the Follicle-Stimulating Hormone (FSH) whose levels rise at menopause could solve bone loss and weight gain Senior Author: Mone Zaidi, MD, PhD, MACP, Director of the Mount Sinai Bone Program and Professor of Medicine (Endocrinology, Diabetes and Bone Disease) at…
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 — the virus that causes the disease — drop sharply over the first three months after infection, decreasing by roughly half every 73 days. If sustained at that rate, the antibodies would disappear within about a year.
The University of Arkansas for Medical Sciences (UAMS) has developed and begun using high-accuracy antibody testing to determine the magnitude of COVID-19 infection in Arkansas and inform the decisions of policymakers.
Scientists at the La Jolla Institute for Immunology (LJI) have discovered a potential new way to better fight a range of infectious diseases, cancers and even autoimmune diseases. The new study, published recently in Nature Immunology, shows how a protein works as a “master regulator” in the immune system.
Recent research by the University at Albany and the New York State Department of Health shows that over 2 million adults in New York were infected with the coronavirus SARS-CoV-2, the virus that causes COVID-19, through late March 2020.
To help accelerate discovery of therapeutic antibodies or antiviral drugs for SARS-CoV-2, the virus that causes COVID-19, Lawrence Livermore National Laboratory has launched a searchable data portal to share its COVID-19 research with scientists worldwide and the general public.
Notre Dame’s Merlin Bruening and a team of scientists have begun research to develop point-of-care antibody tests that would help public health officials to better understand how an individual’s immunity to COVID-19 lasts over time.
Summaries of recent Fred Hutch research findings and other news with links for additional background and media contacts.
Lawrence Livermore National Laboratory researchers have identified an initial set of therapeutic antibody sequences, designed in a few weeks using machine learning and supercomputing, aimed at binding and neutralizing SARS-CoV-2, the virus that causes COVID-19. The research team is performing experimental testing on the chosen antibody designs.
As officials consider how to reopen the country safely, researchers say antibody testing will play an important role in navigating those future decisions. But not all antibody tests are created equal, and the presence of antibodies doesn’t necessarily equate to COVID-19 immunity.
The highly targeted antibody may block the coronaviruses’ ability to enter human lung cells
To assist in the COVID-19 research effort, Lawrence Livermore National Laboratory, Penguin Computing and AMD have reached an agreement to upgrade the Lab’s unclassified, Penguin Computing-built Corona high performance computing (HPC) cluster with an in-kind contribution of cutting-edge AMD Instinct™ accelerators, expected to nearly double the peak performance of the machine.
Iowa State University researchers are developing a portable, inexpensive technology that could allow people to test for the presence of a virus or antibodies without having to go to a medical facility. The technology is still about a year away, but it could come in handy in the event of a resurgence of the coronavirus or for future pandemics.
A newly developed method can detect even low-dose human exposure to microcystins and nodularin in human urine. During harmful algal blooms (HABs), species of cyanobacteria release toxic peptides, including microcystins and nodularin into waterways, impacting wildlife and humans living in these marine environments. These findings are the first to report microcystin concentrations directly from exposed residents impacted by cyanobacteria in Florida, and is a critical step in developing and interpreting clinical diagnostic tests for HABs exposure worldwide.
An international team of scientists has synthetically engineered mosquitoes that halt the transmission of the dengue virus. The development marks the first engineered approach in mosquitoes that targets the four known types of dengue, improving upon previous designs that addressed single strains.